NRx Pharmaceuticals

Historical price data

NRx Pharmaceuticals is a clinical-stage biotech focused on developing lifesaving treatments for suicidal bipolar depression and PTSD, conditions with no currently approved pharmacotherapies. Its core strategy is built on a proprietary NMDA receptor modulation platform, designed to deliver antidepressant efficacy while reducing the suicidality and akathisia associated with standard treatments. The company has achieved significant regulatory momentum, with NRX-101 holding FDA Fast Track and Breakthrough Therapy designations. NRx is advancing a pipeline of neuroplastic therapies and pursuing strategic initiatives, including an ANDA for preservative-free ketamine (NRX-100), to address acute and chronic psychiatric crises.

Proprietary platform for safe modulation of the NMDA receptor, often combined with 5-HT2A receptor targeting, to create non-hallucinogenic, non-addictive neuroplastic therapies for severe psychiatric disorders.

NRX-101 has no direct FDA-approved competitors for suicidal bipolar depression, creating a unique market opportunity. In PTSD and the broader depression space, it competes with established generics and novel therapies, differentiating via its dual NMDA/5-HT2A mechanism designed to avoid hallucinogenic side effects.